304 related articles for article (PubMed ID: 35485219)
21. Current landscape and future directions of bispecific antibodies in cancer immunotherapy.
Wei J; Yang Y; Wang G; Liu M
Front Immunol; 2022; 13():1035276. PubMed ID: 36389699
[TBL] [Abstract][Full Text] [Related]
22. Bispecific antibodies: an innovative arsenal to hunt, grab and destroy cancer cells.
Grandjenette C; Dicato M; Diederich M
Curr Pharm Biotechnol; 2015; 16(8):670-83. PubMed ID: 25941884
[TBL] [Abstract][Full Text] [Related]
23. [Bispecific antibodies: An old story with a bright future… with CAR-T cells!].
Riffard C; Teillaud JL
Bull Cancer; 2021 Oct; 108(10S):S168-S180. PubMed ID: 34920800
[TBL] [Abstract][Full Text] [Related]
24. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
Aldoss I; Bargou RC; Nagorsen D; Friberg GR; Baeuerle PA; Forman SJ
Leukemia; 2017 Apr; 31(4):777-787. PubMed ID: 28028314
[TBL] [Abstract][Full Text] [Related]
25. T-cell-based Immunotherapies for Haematological Cancers, Part A: A SWOT Analysis of Immune Checkpoint Inhibitors (ICIs) and Bispecific T-Cell Engagers (BiTEs).
Rallis KS; Hillyar CRT; Sideris M; Davies JK
Anticancer Res; 2021 Mar; 41(3):1123-1141. PubMed ID: 33788704
[TBL] [Abstract][Full Text] [Related]
26. Bispecific antibody platforms for cancer immunotherapy.
Lameris R; de Bruin RC; Schneiders FL; van Bergen en Henegouwen PM; Verheul HM; de Gruijl TD; van der Vliet HJ
Crit Rev Oncol Hematol; 2014 Dec; 92(3):153-65. PubMed ID: 25195094
[TBL] [Abstract][Full Text] [Related]
27. Development of Bispecific Antibody Derivatives for Cancer Immunotherapy.
He Y; Helfrich W; Bremer E
Methods Mol Biol; 2019; 1884():335-347. PubMed ID: 30465214
[TBL] [Abstract][Full Text] [Related]
28. For whom the T cells troll? Bispecific T-cell engagers in glioblastoma.
Singh K; Hotchkiss KM; Mohan AA; Reedy JL; Sampson JH; Khasraw M
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34795007
[TBL] [Abstract][Full Text] [Related]
29. Generation of a safe and efficacious llama single-domain antibody fragment (vHH) targeting the membrane-proximal region of 4-1BB for engineering therapeutic bispecific antibodies for cancer.
Zhai T; Wang C; Xu Y; Huang W; Yuan Z; Wang T; Dai S; Peng S; Pang T; Jiang W; Huang Y; Zou Y; Xu Y; Sun J; Gong X; Zhang J; Tsun A; Li B; Miao X
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172514
[TBL] [Abstract][Full Text] [Related]
30. Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials.
Hosseini SS; Khalili S; Baradaran B; Bidar N; Shahbazi MA; Mosafer J; Hashemzaei M; Mokhtarzadeh A; Hamblin MR
Int J Biol Macromol; 2021 Jan; 167():1030-1047. PubMed ID: 33197478
[TBL] [Abstract][Full Text] [Related]
31. When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy.
Tapia-Galisteo A; Compte M; Álvarez-Vallina L; Sanz L
Theranostics; 2023; 13(3):1028-1041. PubMed ID: 36793863
[TBL] [Abstract][Full Text] [Related]
32. Characterization of a single reporter-gene potency assay for T-cell-dependent bispecific molecules.
Lee HY; Register A; Shim J; Contreras E; Wu Q; Jiang G
MAbs; 2019 Oct; 11(7):1245-1253. PubMed ID: 31348721
[TBL] [Abstract][Full Text] [Related]
33. Clinical Development and Therapeutic Applications of Bispecific Antibodies for Hematologic Malignancies.
Hays P
Cancer Treat Res; 2022; 183():287-315. PubMed ID: 35551665
[TBL] [Abstract][Full Text] [Related]
34. Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release.
Aschmoneit N; Kühl L; Seifert O; Kontermann RE
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34782429
[TBL] [Abstract][Full Text] [Related]
35. Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy.
Zhang T; Lin Y; Gao Q
Cancer Biol Med; 2023 Mar; 20(3):181-95. PubMed ID: 36971124
[TBL] [Abstract][Full Text] [Related]
36. Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?
Del Bano J; Chames P; Baty D; Kerfelec B
Antibodies (Basel); 2015 Dec; 5(1):. PubMed ID: 31557983
[TBL] [Abstract][Full Text] [Related]
37. "NextGen" Biologics: Bispecific Antibodies and Emerging Clinical Results.
Thakur A; Lum LG
Expert Opin Biol Ther; 2016; 16(5):675-88. PubMed ID: 26848610
[TBL] [Abstract][Full Text] [Related]
38. T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities.
Baeuerle PA; Wesche H
Curr Opin Oncol; 2022 Sep; 34(5):552-558. PubMed ID: 35880455
[TBL] [Abstract][Full Text] [Related]
39. An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors.
Ishiguro T; Sano Y; Komatsu SI; Kamata-Sakurai M; Kaneko A; Kinoshita Y; Shiraiwa H; Azuma Y; Tsunenari T; Kayukawa Y; Sonobe Y; Ono N; Sakata K; Fujii T; Miyazaki Y; Noguchi M; Endo M; Harada A; Frings W; Fujii E; Nanba E; Narita A; Sakamoto A; Wakabayashi T; Konishi H; Segawa H; Igawa T; Tsushima T; Mutoh H; Nishito Y; Takahashi M; Stewart L; ElGabry E; Kawabe Y; Ishigai M; Chiba S; Aoki M; Hattori K; Nezu J
Sci Transl Med; 2017 Oct; 9(410):. PubMed ID: 28978751
[TBL] [Abstract][Full Text] [Related]
40. Bispecific antibodies for polyclonal T-cell engagement.
Baeuerle PA; Kufer P; Lutterbüse R
Curr Opin Mol Ther; 2003 Aug; 5(4):413-9. PubMed ID: 14513685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
